PLXP VS JNJ Stock Comparison

PerformanceForecastSentimentTechnicalsEarningsProfitVolatilityAnalyst Price TargetsDividend
PerformanceForecastSentimentTechnicalsEarningsProfitVolatilityAnalyst Price TargetsDividend

Performance

PLXP
10/100

PLXP returned -96.94% in the last 12 months. Based on the other stocks in its sector with an average return of -31.58%, its performance is below average giving it a grade of 10 of 100.

JNJ
73/100

JNJ returned -15.84% in the last 12 months. Based on SPY's performance of -20.60%, its performance is above average giving it a score of 73 of 100.

Forecast

PLXP
75/100

1 analysts offer 12-month price forecasts for PLXP. Together, they have an average target of 0, the most optimistic forecast put PLXP at 0 within 12-months and the most pessimistic has PLXP at 0.

JNJ

"Forecast" not found for JNJ

Sentiment

PLXP
71/100

PLXP had a bullish sentiment score of 70.81% across Twitter and StockTwits over the last 12 months. It had an average of 9.26 posts, 0.97 comments, and 3.56 likes per day.

JNJ
72/100

JNJ had a bullish sentiment score of 71.87% across Twitter and StockTwits over the last 12 months. It had an average of 205.31 posts, 3,341.61 comments, and 16,552.61 likes per day.

Technicals

PLXP
10/100

PLXP receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

JNJ
14/100

JNJ receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

PLXP
10/100

PLXP has missed earnings 9 times in the last 20 quarters.

JNJ
100/100

JNJ has missed earnings 0 times in the last 20 quarters.

Profit

PLXP
41/100

Out of the last 20 quarters, PLXP has had 8 profitable quarters and has increased their profits year over year on 6 of them.

JNJ
74/100

Out of the last 20 quarters, JNJ has had 19 profitable quarters and has increased their profits year over year on 9 of them.

Volatility

PLXP
30/100

PLXP has had a lower than average amount of volatility over the last 12 months giving it a grade of 29 of 100.

JNJ
43/100

JNJ has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

Analyst Price Targets

PLXP

"Analyst Price Targets" not found for PLXP

JNJ
63/100

23 analysts offer 12-month price targets for JNJ. Together, they have an average target of 176.5, the most optimistic target put JNJ at 205 within 12-months and the most pessimistic has JNJ at 90.

Dividend

PLXP

"Dividend" not found for PLXP

JNJ
100/100

JNJ's most recent dividend was $0.90 per share, based on a share price of $145.60. It was a payout ratio of 61.39% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

PLx Pharma Inc. Common Stock Summary

Nasdaq / PLXP
Healthcare
Drug Manufacturers—Specialty & Generic
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.

Johnson & Johnson Summary

New York Stock Exchange / JNJ
Healthcare
Drug Manufacturers - General
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.